SecBot SecBot

RAPH

Raphael Pharmaceutical Inc.
OTC· Medicinal Chemicals & Botanical Products· Inc. NV· CIK 0001415397 Biotech & Drug Discovery
$1.51 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $1.51
1 year
+277.5%
from $0.4000 · Oct 27
30 days
+7.9%
from $1.40
52-week range
$0.4000–1.51
0% from high · low Oct 27
Avg volume 20D
5
Oct 16 spike 100
Insider net
$0
no open-market trades · 12 mo
Filing reports
2
analyzed by SecBot
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1
Strongest NEUTRAL Raphael Pharmaceutical entered into a 12-month, $180,000 managed AI services agreement with AIcreatesAI for…
All reports →

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • TrendUPTREND

    7% above its 50-day average. New closing high $1.51 on Oct 23.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 1, 2026 SEC
Raphael Pharmaceutical entered into a 12-month, $180,000 managed AI services agreement with AIcreatesAI for digital…
8-K — Impact 3/10
Jul 17, 2026 SEC
Raphael Pharmaceutical Inc. filed an 8-K reporting the voluntary resignations of Chairman Ajay Kumar Dhadha (effective…
8-K — Impact 4/10
Nov 20, 2025 Insider
Louria Hayon Igal acquired via exercise 350,000 shares
Chief Technology Officer @ $0.0100 ($3.5K)
Nov 20, 2025 Insider
Louria Hayon Igal acquired via exercise 350,000 shares
Chief Technology Officer

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Nov 20, 2025
Louria Hayon Igal
Chief Technology Officer
EXERCISE$3.5K
Nov 20, 2025
Louria Hayon Igal
Chief Technology Officer
EXERCISE350,000 sh

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

SecBot reports

2 filings · 0 bullish · 0 bearish · 2 neutral
All RAPH filing & press-release reports (2)